Skip to content
PeptideSport
Good Girl Rx logo

Provider review

Good Girl Rx review

Received an FDA warning letter dated February 2026 for "FDA-approved" marketing claims

Semaglutide starts at $134 a month and tirzepatide at $235. Its operating company received an FDA warning letter in February 2026 over site language calling its compounded products "FDA-approved"; the wording has since been corrected, with no fines reported.

Received an FDA warning letter in February 2026 see the FDA’s warning-letter database.

Verified August 2026

Straight talk: how we earn — some, not all, of these are affiliate links; start a program through one and we may earn a commission at no extra cost to you. Straight about the rest, too: the write-ups say what each provider is actually worth, and a commission does not change a word of them. Full disclosure here.

On this page

The verdict

Good Girl Rx's founder story is real and unusually well-documented for this category — Savannah Chrisley bought the company outright after an initial partnership, a fact confirmed across multiple outlets. But the single most important fact here is the FDA warning letter dated February 2026, confirmed via the agency's own index, citing marketing language that overstated FDA approval for products that don't have it. The company corrected the language within its 15-day window, and no penalty was issued — worth knowing both that the finding is real and that it was addressed, rather than treating it as either disqualifying or dismissible.

Good Girl Rx is not ranked on any of our rankings. This is a standalone read of what the company publishes about itself — the providers we do rank in this category are on our semaglutide provider ranking. Nothing on this page is a performance claim — see the evidence review for what these compounds do and do not do.

Who it is for, and who it is not

A good fit if

  • You want multiple formats (injectable, microdose, ODT pills) for both semaglutide and tirzepatide from one provider
  • You've read the FDA warning letter and are satisfied the site has corrected the cited language
  • You want brand-name options (Ozempic, Wegovy, Zepbound, Mounjaro) alongside compounded

Look elsewhere if

  • You want a provider with a clean current regulatory record — this one has a February 2026 FDA warning letter
  • You want a named compounding pharmacy — none is disclosed
  • You're wary of a very new brand (founded 2025) with a short independent track record

What it actually costs

What they advertise

Compounded semaglutide injectable: from $134/mo on goodgirlrx.com.

What you actually pay, month to month

The $134 figure is for semaglutide only; tirzepatide injectable runs higher, from $235/mo. ODT pill formats and brand-name options are priced separately and higher still.

The commitment trap

The $134 headline is the semaglutide price only — tirzepatide, offered on the same site, starts at $235/mo instead.

Checked live on Good Girl Rx's own site at https://goodgirlrx.com in August 2026. Prices change without notice — confirm before you buy. Work out what a vial actually gives you with our peptide dose calculator.

What is included

The cheapest headline number in this category is often the one with the least attached to it. Here is what Good Girl Rx bundles in, and what it does not.

Clinician consult

Provider evaluation

a one-time video or phone consult is required in New Mexico, Kansas, West Virginia, Louisiana, and Mississippi due to state telehealth law.

Bloodwork / labs

Not published.

Follow-ups and dose changes

No cadence published.

Human support

Not published.

Injection supplies

Included in the medication price.

Shipping

No terms published.

Pharmacy, labs and oversight

The pharmacy

Not named; described only as independent state-licensed compounding pharmacies.

Oversight

No cadence published.

Compounded peptides are not FDA-approved products, and a 503A pharmacy compounds for a named patient while a 503B outsourcing facility manufactures in batches under CGMP. Neither is a quality guarantee on its own — a named facility is simply a fact you can check, and an unnamed “partner pharmacy network” is not. Our guide to verifying a certificate of analysis covers what to ask for.

Where you can get it

All 50 states, with additional consult requirements in New Mexico, Kansas, West Virginia, Louisiana, and Mississippi.

The honest cons

The part they would rather you skipped

Good Girl, LLC dba GoodGirlRx received an FDA warning letter dated February 2026, confirmed via the FDA's own warning-letter index, citing site language including "FDA-approved meds" and "clinically proven GLP-1 results" as false or misleading for unapproved compounded products — corrected within the agency's 15-day window, with no fines or disciplinary action reported.

  • FDA warning letter dated February 2026 for "FDA-approved" and "clinically proven" marketing claims
  • Compounding pharmacy never named
  • Very new brand with a short independent track record
  • Five states require an additional consult step due to state telehealth law

None of this is unique to Good Girl Rx — the whole category shares it. What we hold against a provider is the part it hides, and the ways vendors hide things are cataloged in our vendor red-flags guide.

How it compares

Read this before you buy

A provider comparison is half the decision. The other half is whether the compound does anything for you at all — and whether it is allowed where you compete. Growth-hormone secretagogues are banned in tested sport, year-round, and a prescription does not change that.

Facts on this page reflect Good Girl Rx's own public disclosures when we last checked them, in August 2026. Prices and terms change without notice — confirm on Good Girl Rx's site before you buy. Provider names and logos on this page identify the company under review; their use does not imply endorsement, sponsorship or affiliation. This page is informational and not medical advice; compounded peptides are not FDA-approved, and growth-hormone secretagogues are banned in tested sport year-round. See our disclosure and editorial policy.